UVM wins $38M ARPA-H contract: Developing ReSCUED real-time AI digital twins to personalize ICU sepsis and trauma immunotherapy.

Eko Health clears FDA 510(k) for CORE 300: Bringing automated structural heart triage to everyday physical exams at acoustic price parity.

RIVANNA secures FDA clearance for BoneEnhance: Automating 3D bone and musculoskeletal segmentation on Accuro XV ultrasound.

Follow the Money & Investor Signal: Capital concentrates in point-of-care diagnostic leverage and high-acuity computational simulation.

Led by trauma surgeon Dr. Gary An, the ReSCUED project models disordered systemic immune responses driving sepsis, burns, and severe trauma, drawing patient blood every six hours to update a predictive computational digital twin.

An AI 'virtual consultant' layer simulates the physiological impact of FDA-approved therapeutics in silico before clinicians administer them at the bedside, ranking intervention strategies for individual patient biology.

Key technology partners include the DNA Medicine Institute (supplying space-station-grade bedside molecular testing) and InflammaSense (providing vagus nerve wearables to track systemic inflammatory tone).

Clinical trials and multi-center validation will span Wake Forest University, the University of Alabama at Birmingham, and Washington University in St. Louis.

The project targets a minimum 25% reduction in ICU length of stay, addressing an acute care burden that affects 4.6 million Americans annually at an estimated cost of $70 billion

· The CORE 300 integrates Eko's FDA-cleared AI algorithms to automatically detect heart murmurs, structural heart disease, and pulmonary abnormalities during routine physical exams in both pediatric and adult patients.

Priced competitively with traditional premium analog acoustic stethoscopes, the device aims to eliminate the hardware price premium that has previously limited AI stethoscope adoption to specialized cardiology suites.

The hardware streams acoustic phonocardiograms and wireless ECG telemetry directly into primary care EHR flowsheets, enabling immediate telemedicine sharing and longitudinal sound tracking.

Clinical studies show that AI auscultation identifies valvular heart disease and structural defects with greater than 85% sensitivity, substantially outperforming standard primary care stethoscope auscultation.

The commercial launch expands Eko's enterprise health system footprint as hospital networks standardize outpatient primary care physical exams on AI-connected diagnostic tools.

BoneEnhance automatically segments bony surfaces, cartilage interfaces, and surrounding soft tissues in real time, converting raw volumetric ultrasound data into standardized 3D skeletal anatomical maps during point-of-care image review

The platform bridges the gap between ultrasound image acquisition and automated clinical interpretation, designed to aid anesthesiologists, orthopedic surgeons, and emergency physicians in spinal and musculoskeletal procedures.

The software runs natively on the portable Accuro XV ultrasound console, which achieved initial volumetric imaging clearance earlier this year for conventional and superficial musculoskeletal applications.

By providing automated 3D bone visualization without ionizing radiation, the system offers an alternative to CT scans for bedside needle guidance and orthopedic trauma assessments.

Commercial rollout will target hospital anesthesia departments, acute pain services, and orthopedic outpatient surgical centers across North America and Europe.

ARPA-H ReSCUED Digital Twin Milestones: Computational validation benchmarks over the next 12 months as UVM integrates continuous bedside molecular sensor telemetry from the DNA Medicine Institute.

Primary Care Conversion Rates for Eko CORE 300: How rapidly large medical groups and health systems transition entire primary care clinician cohorts from traditional acoustic stethoscopes to AI-connected digital devices.

Hospital Anesthesiology Adoption of 3D Ultrasound AI: Whether spinal anesthesia placement failure rates and procedural times decrease measurably as RIVANNA's BoneEnhance deploys across academic surgical suites.

University of Vermont (ReSCUED): $38M milestone-based ARPA-H contract to build real-time physiological digital twins for ICU care.

Eko Health: Commercial launch of FDA-cleared CORE 300 AI stethoscope targeting mass-market primary care adoption.

RIVANNA: Secured FDA 510(k) clearance for BoneEnhance 3D machine learning module on Accuro XV ultrasound.

HLTH 2026 Global Convening (November 15-18, 2026 | Las Vegas, Nevada): The premier industry gathering for digital health leaders, payers, and health systems shaping commercial AI agendas for 2027.

ARPA-H SURPASS National Proposers Day (November 6, 2026 | Austin, TX & Virtual): Federal technical briefing for biopharma sponsors and AI developers bidding on adaptive clinical trial overhaul programs.

RSNA 2026 (Radiological Society of North America) (November 29 - December 3, 2026 | McCormick Place, Chicago, IL): The global epicenter for clinical imaging AI, POCUS innovation, and volumetric ultrasound commercialization.

Eko CORE 300: FDA-cleared next-generation AI stethoscope combining digital amplification, phonocardiogram visualization, and automated structural heart triage at analog price parity.

RIVANNA BoneEnhance: FDA-cleared 3D machine learning module for Accuro XV ultrasound that automatically segments bone and musculoskeletal anatomy in real time.

5 Digital Twin OS: ARPA-H-funded computational ICU digital twin platform simulating patient-specific immune response trajectories and ranking pharmacologic therapies.

Eko Health: Point-of-care cardiovascular and pulmonary AI company securing FDA 510(k) clearance for its CORE 300 connected stethoscope.

RIVANNA: Charlottesville medtech developer expanding its Accuro XV ultrasound platform with FDA-cleared 3D machine learning bone segmentation.

InflammaSense: Wearable medical technology company partnering on the $38M ARPA-H ReSCUED program to track vagus nerve inflammatory telemetry.

Physiological Digital Twins in the ICU: The ReSCUED $38M Blueprint: An in-depth analysis of UVM's $38M ARPA-H project modeling sepsis and trauma trajectories, evaluating six-hour molecular biomarker cycles, in silico drug response simulation, and the clinical economics of cutting ICU length of stay by 25%.

AI at the Stethoscope: Eko CORE 300 and Point-of-Care Auscultation Economics: Examining how pricing AI-enabled diagnostic hardware at acoustic parity eliminates hospital procurement barriers, comparing

detection sensitivity across primary care auscultation, and evaluating downstream cardiovascular referral triage.

3D Volumetric Ultrasound: RIVANNA BoneEnhance and Point-of-Care Skeletal AI: An operational guide to automated machine learning bone segmentation on portable ultrasound, analyzing radiation-free bedside imaging for anesthesiology and orthopedic trauma, and hospital ROI across outpatient surgical centers.